Trial · NCT00906035
The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)
NCT00906035, Not applicable, Terminated, University of Pennsylvania; results first posted 2017-09-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD). Trials, record NCT00906035. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00906035
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)
- NCT number
- NCT00906035
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 25 participants, actual
- Lead sponsor
- University of Pennsylvania
- Conditions
- Peripheral Arterial Disease
- Interventions
- Dipyridamole 200mg and Aspirin 25mg bid:, Dipyridamole 200 mg bid, Aspirin 25 mg bid
- First posted
- 2009-05-21
- Last updated
- 2017-09-05
- Results first posted
- 2017-09-05
- Limitations and caveats
Study encountered difficulty while attempting to find subjects who met all inclusion/exclusion criteria.0 indicated because no analysis was done on samples obtained. Data could not be analyzed due to insufficient number of participants enrolled.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Present Study is Designed to Explore Two Potential Mechanisms Which Have Been Linked to Dipyridamole Action on the Vessel Wall; Modulation of Vascular Eicosanoid Generation and Prevention of Oxidant Stress. | Predose and dosing days 30, 90 and 180 | No analysis could be performed due to the insufficent number of participants enrolled. Data were not collected due to study termination related to the difficulty finding participants that matched the inclusion/exclusion criteria. |
| Secondary | Assess the Functional Consequences of Dipyridamole Action, Alone and in Combination With Aspirin Compared With Aspirin Alone on Local Measurements of Flow and Oxygenation. Blood Flow Reporting to Added Table. | Predose and dosing days 30, 90 and 180. | Done by doppler ultrasound. Data could not be analyzed due to insufficient number of participants enrolled. Data were not collected due to study termination related to the difficulty finding participants that matched the inclusion/exclusion criteria. |
| Secondary | Assess the Functional Consequences of Dipyridamole Action, Alone and in Combination With Aspirin Compared With Aspirin Alone on Local Measurements of Flow and Oxygenation. Reporting Blood Oxygenation. | Predose and dosing days 30, 90 and 180. | Reporting blood oxygenation. Data could not be analyzed due to insufficient number of participants enrolled. Difficulty finding participants who fit into the inclusion/exclusion criteria. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Present Study is Designed to Explore Two Potential Mechanisms Which Have Been Linked to Dipyridamole Action on the Vessel Wall; Modulation of Vascular Eicosanoid Generation and Prevention of Oxidant Stress. | Predose and dosing days 30, 90 and 180 | Data could not collected due to study termination related to the difficulty finding participants that matched the inclusion/exclusion criteria. Data could not be analyzed due to insufficient number of participants enrolled. | ||
| SECONDARY | Assess the Functional Consequences of Dipyridamole Action, Alone and in Combination With Aspirin Compared With Aspirin Alone on Local Measurements of Flow and Oxygenation. Blood Flow Reporting to Added Table. | Predose and dosing days 30, 90 and 180. | Data could not be analyzed due to insufficient number of participants enrolled. Data were not collected due to study termination related to the difficulty finding participants that matched the inclusion/exclusion criteria. | ||
| SECONDARY | Assess the Functional Consequences of Dipyridamole Action, Alone and in Combination With Aspirin Compared With Aspirin Alone on Local Measurements of Flow and Oxygenation. Reporting Blood Oxygenation. | Predose and dosing days 30, 90 and 180. | Data could not be analyzed due to insufficient number of participants enrolled. Data were not collected due to study termination related to the difficulty finding participants that matched the inclusion/exclusion criteria. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dipyridamole 200mg and Aspirin 25mg Bid | 8 | |
| Overall Study | STARTED | Dipyridamole 200 mg Bid | 9 | |
| Overall Study | STARTED | Aspirin 25 mg Bid | 8 | |
| Overall Study | COMPLETED | Dipyridamole 200mg and Aspirin 25mg Bid | 6 | |
| Overall Study | COMPLETED | Dipyridamole 200 mg Bid | 6 | |
| Overall Study | COMPLETED | Aspirin 25 mg Bid | 8 | |
| Overall Study | NOT COMPLETED | Dipyridamole 200mg and Aspirin 25mg Bid | 2 | |
| Overall Study | NOT COMPLETED | Dipyridamole 200 mg Bid | 3 | |
| Overall Study | NOT COMPLETED | Aspirin 25 mg Bid | 0 |
Source ClinicalTrials.gov
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | intermittent claudication | Vascular disorders | Dipyridamole 200mg and Aspirin 25mg Bid | 2 | 8 | |
| other | intermittent claudication | Vascular disorders | Dipyridamole 200 mg Bid | 3 | 9 | |
| other | intermittent claudication | Vascular disorders | Aspirin 25 mg Bid | 2 | 8 | |
| other | Angina | Cardiac disorders | Dipyridamole 200mg and Aspirin 25mg Bid | 1 | 8 | |
| other | Angina | Cardiac disorders | Dipyridamole 200 mg Bid | 0 | 9 | |
| other | Angina | Cardiac disorders | Aspirin 25 mg Bid | 1 | 8 | |
| other | Diarrhea | General disorders | Dipyridamole 200mg and Aspirin 25mg Bid | 0 | 8 | |
| other | Diarrhea | General disorders | Dipyridamole 200 mg Bid | 1 | 9 | |
| other | Diarrhea | General disorders | Aspirin 25 mg Bid | 1 | 8 | |
| other | Headache | General disorders | Dipyridamole 200mg and Aspirin 25mg Bid | 2 | 8 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dipyridamole 200mg and Aspirin 25mg Bid | ||
| Total, all-cause mortality | Dipyridamole 200 mg Bid | ||
| Total, all-cause mortality | Aspirin 25 mg Bid | ||
| Total, other adverse events | Dipyridamole 200mg and Aspirin 25mg Bid | 5 | 8 |
| Total, other adverse events | Dipyridamole 200 mg Bid | 4 | 9 |
| Total, other adverse events | Aspirin 25 mg Bid | 5 | 8 |
| Total, serious adverse events | Dipyridamole 200mg and Aspirin 25mg Bid | 2 | 8 |
| Total, serious adverse events | Dipyridamole 200 mg Bid | 1 | 9 |
| Total, serious adverse events | Aspirin 25 mg Bid | 1 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00906035
GET https://conductscience.org/api/trials/v1/NCT00906035/events?page=2